• Akamatsu N, Sugawara Y, Kaneko J, Kishi Y, Makuuchi M 2005 Risk factors of cytomegalovirus infection after living donor liver transplantation. Hepatogastroenterology 52: 197-199.

• Akamatsu N, Sugawara Y, Nakajima J, Kishi Y, Kaneko J, Makuuchi M 2005 Cryptococcosis after living donor liver transplantation: report of three cases. Transpl. Infect. Dis. 7: 26-29. *

• Akamatsu N, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, Makuuchi M 2007 Impact of live donor age (>/=50) on liver transplantation. Transplant. Proc. 39: 3189-3193. *

• Alison MR, Choong C, Lim S 2007 Application of liver stem cells for cell therapy. Semin. Cell Dev. Biol. 18: 819-826. *

• Ambrosino G, Naso A, Feltracco P, Carraro P, Basso SM, Varotto S, Cillo U, Zanus 2003 Cytokines and liver failure: modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS). Acta Biomed. Ateneo Parmense 74 Suppl. 2: 7-9.

• Anand AC 2003 Bioartificial liver support for fulminant hepatic failure. Indian J. Gastroenterol. 22 Suppl. 2: S69-S74.

• Armendariz-Borunda J, Rincon AR, Munoz-Valle JF, Bueno-Topete M, Oregon-Romero E, Islas-Carbajal MC, Medina-Preciado D, Gonzalez-Garcia I, Bautista CA, Garcia-Rocha S, Godoy J, Vazquez-Del Mercado M, Troyo-Sanroman R, Arellano-Olivera I, Lucano S, et al 2008 Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. J. Investig. Med. Sep 12 [Epub ahead of print].

• Auth MK, Woitaschek D, Beste M, Schreiter T, Kim HS, Oppermann E, Joplin RE, Baumann U, Hilgard P, Nadalin S, Markus BH, Blaheta RA 2005 Preservation of the synthetic and metabolic capacity of isolated human hepatocytes by coculture with human biliary epithelial cells. Liver Transpl. 11: 410-419. *

• Bachli EB, Schuepbach RA, Maggiorini M, Stocker R, Mullhaupt B, Renner EL 2007 Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications. Liver Int. 27: 475-484. *

• Balis UJ, Yarmush ML, Toner M 2002 Bioartificial liver process monitoring and control systems with integrated systems capability. Tissue Eng. 8: 483-498.

• Banares Canizares R, Catalina Rodriguez MV 2003 Indications and therapeutic possibilities of albumin dialysis (MARS). Rev. Esp. Enferm. Dig. 95: 876-889.

• Batra Y, Acharya SK 2003 Acute liver failure: prognostic markers. Indian J. Gastroenterol. 22 Suppl. 2: S66-S68.

• Benoist S, Nordlinger B 2001 The internal bioartifical liver. J. Soc. Biol. 195: 91-96.

• Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC 2008 Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol. 48: 983-992.

• Bickston SJ, Comerford LW, Cominelli F 2003 Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523.

• Broelsch CE, Testa G, Alexandrou A, Malago M 2002 Living related liver transplantation: medical and social aspects of a controversial therapy. Gut 50: 143-145. *

• Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW 1993 The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 5: 327-337. *

• Cao S, Esquivel CO, Keeffe EB 1998 New approaches to supporting the failing liver. Annu. Rev. Med. 49: 85-94. *

• Chan C, Berthiaume F, Lee K, Yarmush ML 2003 Metabolic flux analysis of cultured hepatocytes exposed to plasma. Biotechnol. Bioeng. 81: 33-49. *

• Chan C, Berthiaume F, Nath BD, Tilles AW, Toner M, Yarmush ML 2004 Hepatic tissue engineering for adjunct and temporary liver support: critical technologies. Liver Transpl. 10: 1331-1342. *

• Chan C, Berthiaume F, Washizu J, Toner M, Yarmush ML 2002 Metabolic pre-conditioning of cultured cells in physiological levels of insulin: generating resistance to the lipid-accumulating effects of plasma in hepatocytes. Biotechnol. Bioeng. 78: 753-760. *

• Chan C, Hwang D, Stephanopoulos GN, Yarmush ML, Stephanopoulos G 2003 Application of multivariate analysis to optimize function of cultured hepatocytes. Biotechnol. Prog. 19: 580-598. *

• Chazouilleres O 2004 Primary sclerosing cholangitis and biliary malignancy: a glimmer of hope? J. Hepatol. 40: 857-859. *

• Chen Z, Ding Y, Li G 2005 Configuration of a new bioartificial liver support system and in vitro evaluation of its functions. Ann. Clin. Lab. Sci. 35: 7-14.

• Cheung C, Yu AM, Chen CS, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ 2006 Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J. Pharmacol. Exp. Ther. 316: 1328-1334. *

• Chiu A, Fan ST 2006 MARS in the treatment of liver failure: controversies and evidence. Int. J. Artif. Organs 29: 660-667.

• Cho CH, Parashurama N, Park EY, Suganuma K, Nahmias Y, Park J, Tilles AW, Berthiaume F, Yarmush ML 2008 Homogeneous differentiation of hepatocyte-like cells from embryonic stem cells: applications for the treatment of liver failure. FASEB J. 22: 898-909. *

• Clayton PT 2006 Hereditary liver diseases: screening strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 42-43. *

• Conese M, Boyd AC, Di Gioia S, Auriche C, Ascenzioni F 2007 Genomic context vectors and artificial chromosomes for cystic fibrosis gene therapy. Curr. Gene Ther. 7: 175-187.

• Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ 2003 Bioartificial liver support devices: historical perspectives. ANZ J. Surg. 73: 739-748. *

• Creuzot-Garcher C, Lafontaine PO, Brignole F, Pisella PJ, d'Athis P, Bron A, Lapierre V, Baudouin C 2004 Treating severe dry eye syndromes with autologous serum. J. Fr. Ophtalmol. 27: 346-351.

• Cucchetti A, Vivarelli M, Heaton ND, Phillips S, Piscaglia F, Bolondi L, La Barba G, Foxton MR, Rela M, O'grady J, Pinna AD 2007 Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. Gut 56: 253-258. *

• Czaja AJ 2007 Autoimmune liver disease and rheumatic manifestations. Curr. Opin. Rheumatol. 19: 74-80.

• Czaja AJ 2007 Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262.

• Dan YY, Yeoh GC 2008 Liver stem cells: a scientific and clinical perspective. J. Gastroenterol. Hepatol. 23: 687-698. *

• DeMar JC Jr, Dimartino C, Baca AW, Lefkowitz W, Salem N Jr 2008 Effect of dietary docosaheaxenoic acid on the net accumulation of docosaheaxenoic acid biosynthesized from alpha-linolenic acid in organs of young rat. J. Lipid Res. 49: 1963-1980. *

• Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, Am Esch JS 2nd, Lerut J, Nyberg SL, Salizzoni M, Fagan EA, de Hemptinne B, Broelsch CE, et al 2004 Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann. Surg. 239: 660-667. *

• Di Campli C, Gasbarrini G, Gasbarrini A 2003 Review article: a medicine based on cell transplantation - is there a future for treating liver diseases? Aliment. Pharmacol. Ther. 18: 473-480. *

• Di Campli C, Nestola M, Piscaglia AC, Santoliquido A, Gasbarrini G, Pola P, Gasbarrini A 2003 Cell-based therapy for liver diseases. Eur. Rev. Med. Pharmacol. Sci. 7: 41-44.

• Di Nicuolo G, Kerkhove MP, Hoekstra R, Beld MG, Amoroso P, Battisti S, Starace M, Florio E, Scuderi V, Scala S, Bracco A, Mancini A, Chamuleau RA, Calise F 2005 No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver. Xenotransplantation 12: 286-292. *

• Dulundu E, Sugawara Y, Makuuchi M 2004 Revolution and refinement of surgical techniques for living donor partial liver transplantation. Yonsei Med. J. 45: 1076-1088. *

• Faenza S, Mancini E, Petrini F, Santoro A, Zanoni A, Martinelli G 2004 Role of intensive therapy in liver transplant recipients: experience in blood purification and biosynthetic techniques. Transplant. Proc. 36: 555-557. *

• Filippi C, Keatch SA, Rangar D, Nelson LJ, Hayes PC, Plevris JN 2004 Improvement of C3A cell metabolism for usage in bioartificial liver support systems. J. Hepatol. 41: 599-605. *

• Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S, Toda G; Intractable Liver Diseases Study Group of Japan 2008 Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol. Res. 38: 646-657. *

• Fujiyama Y, Yamagishi Y, Kikuchi M, Shimoji K, Kato S, Nagata H, Saito H, Hibi T, Mishiro S 2007 A case of fulminant hepatitis E treated with artificial liver support. Nippon Shokakibyo Gakkai Zasshi 104: 219-225.

• Galvao FH, de Andrade Junior DR, de Andrade DR, Martins BC, Marson AG, Bernard CV, Dos Santos SA, Bacchella T, Machado MC 2006 Hepatocyte transplantation: state of the art. Hepatol. Res. 36: 237-247.

• Gan JH, Zhou XQ, Qin AL, Luo EP, Zhao WF, Yu H, Xu J 2005 Hybrid artificial liver support system for treatment of severe liver failure. World J. Gastroenterol. 11: 890-894. *

• George J 2004 Artificial liver support systems. J. Assoc. Physicians India. 52: 719-722.

• Gerlach JC, Zeilinger K, Patzer II JF 2008 Bioartificial liver systems: why, what, whither? Regen. Med. 3: 575-595.

• Gluud C, Brok J, Gong Y, Koretz RL 2007 Hepatology may have problems with putative surrogate outcome measures. J. Hepatol. 46: 734-742. *

• Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta JA, Blesa A, Montejo JC, Garcia de Lorenzo A, Mesejo A 2007 Liver dysfunction associated with artificial nutrition in critically ill patients. Crit. Care 11: R10. *

• Guglielmi FW, Regano N, Mazzuoli S, Fregnan S, Leogrande G, Guglielmi A, Merli M, Pironi L, Penco JM, Francavilla A 2008 Cholestasis induced by total parenteral nutrition. Clin. Liver Dis. 12: 97-110.

• Guo L, Haga S, Enosawa S, Naruse K, Harihara Y, Sugawara Y, Irani K, Makuuchi M, Ozaki M 2004 Improved hepatic regeneration with reduced injury by redox factor-1 in a rat small-sized liver transplant model. Am. J. Transplant. 4: 879-887. *

• Harimoto N, Taketomi A, Kitagawa D, Kuroda Y, Itoh S, Giona T, Tanaka S, Shirabe K, Shimada M, Maehara Y 2005 The newly established human hepatocyte cell line: application for the bioartificial liver. J. Hepatol. 42: 557-564. *

• Hasegawa K, Sugawara Y, Imamura H, Ikeda M, Kokudo N, Makuuchi M 2005 Living donor liver transplantation for primary biliary cirrhosis: retrospective analysis of 50 patients in a single center. Transpl. Int. 18: 794-799. *

• Hashimoto T, Sugawara Y, Tamura S, Hasegawa K, Kishi Y, Kokudo N, Makuuchi M 2006 Estimation of standard liver volume in Japanese living liver donors. J. Gastroenterol. Hepatol. 21: 1710-1713. *

• Hayashi H, Shimizu K, Tani T, Takamura H, Takeshita M, Funaki K, Kitagawa H, Kayahara M, Ota T, Miwa K 2005 Multiple organ failure caused by end-stage liver disease successfully treated with living donor liver transplantation using perioperative percutaneous cardiopulmonary support: a case report. Transplant. Proc. 37: 1101-1103.

• Haywood S, Muller T, Mackenzie AM, Muller W, Tanner MS, Heinz-Erian P, Williams CL, Loughran MJ 2004 Copper-induced hepatotoxicosis with hepatic stellate cell activation and severe fibrosis in North Ronaldsay lambs: a model for non-Wilsonian hepatic copper toxicosis of infants. J. Comp. Pathol. 130: 266-277. *

• Higgins PD, Fontana RJ 2003 Liver transplantation in acute liver failure. Panminerva. Med. 45: 85-94.

• Hiramatsu A, Takahashi S, Aikata H, Azakami T, Katamura Y, Kawaoka T, Uka K, Yamashina K, Takaki S, Kodama H, Jeong SC, Imamura M, Kawakami Y, Chayama K 2008 Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J. Gastroenterol. Hepatol. 23: 1216-1222. *

• Hodgson H 2003 Liver cells: biology to therapeutics. Clin. Med. 3: 161-165. *

• Hui T, Rozga J, Demetriou AA 2001 Bioartificial liver support. J. Hepatobiliary Pancreat. Surg. 8: 1-15. *

• Ichai P, Samuel D 2004 Treatment of patients with hepatic failure: the difficult place of liver support systems. J. Hepatol. 41: 694-695. *

• Iwahori T, Matsuura T, Maehashi H, Sugo K, Saito M, Hosokawa M, Chiba K, Masaki T, Aizaki H, Ohkawa K, Suzuki T 2003 CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 37: 665-673. *

• Jimenez Jimenez FJ, Montejo Gonzalez JC, Nunez Ruiz R 2005 Artificial nutrition in liver failure. Nutr. Hosp. 20 Suppl. 2: 22-24.

• Kaneko J, Sugawara Y, Akamatsu N, Kokudo N, Makuuchi M 2004 Spleen volume and platelet number changes after living donor liver transplantation in adults. Hepatogastroenterology 51: 262-263.

• Kaneko J, Sugawara Y, Togashi J, Kishi Y, Akamatsu N, Makuuchi M 2004 Simultaneous hepatic artery and portal vein thrombosis after living donor liver transplantation. Transplant. Proc. 36: 3087-3089.

• Kay MA, Fausto N 1997 Liver regeneration: prospects for therapy based on new technologies. Mol. Med. Today 3: 108-115.

• Khetani SR, Szulgit G, Del Rio JA, Barlow C, Bhatia SN 2004 Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling. Hepatology 40: 545-554. *

• Kishi Y, Sugawara Y, Akamatsu N, Kaneko J, Matsui Y, Kokudo N, Makuuchi M 2004 Sharing the middle hepatic vein between donor and recipient: left liver graft procurement preserving a large segment VIII branch in donor. Liver Transpl. 10: 1208-1212. *

• Kishi Y, Sugawara Y, Kaneko J, Matsui Y, Akamatsu N, Makuuchi M 2004 Classification of portal vein anatomy for partial liver transplantation. Transplant. Proc. 36: 3075-3076.

• Kishi Y, Sugawara Y, Matsui Y, Akamatsu N, Motomura N, Takamoto S, Makuuchi M 2005 Alternatives to the double vena cava method in partial liver transplantation. Liver Transpl. 11: 101-103. *

• Kishi Y, Sugawara Y, Tamura S, Kaneko J, Akamatsu N, Togashi J, Makuuchi M 2005 Is blood eosinophilia an effective predictor of acute rejection in living donor liver transplantation? Transpl. Int. 18: 1147-1151. *

• Kishi Y, Sugawara Y, Tamura S, Kaneko J, Kokudo N, Makuuchi M 2006 Impact of incidentally found hepatocellular carcinoma on the outcome of living donor liver transplantation. Transpl. Int. 19: 720-725. *

• Kishi Y, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Makuuchi M 2007 Histologic eosinophilia as an aid to diagnose acute cellular rejection after living donor liver transplantation. Clin. Transplant. 21: 214-218. *

• Kitayama T, Funayama Y, Fukushima K, Shibata C, Takahashi K, Ogawa H, Ueno T, Hashimoto A, Sasaki I 2005 Anal function during pregnancy and postpartum after ileal pouch anal anastomosis for ulcerative colitis. Surg. Today 35: 211-215.

• Kobayashi N, Okitsu T, Nakaji S, Tanaka N 2003 Hybrid bioartificial liver: establishing a reversibly immortalized human hepatocyte line and developing a bioartificial liver for practical use. J. Artif. Organs 6: 236-244.

• Kokudo N, Sugawara Y, Imamura H, Sano K, Makuuchi M 2005 Tailoring the type of donor hepatectomy for adult living donor liver transplantation. Am. J. Transplant. 5: 1694-1703. *

• Kokudo N, Sugawara Y, Kaneko J, Imamura H, Sano K, Makuuchi M 2004 Reconstruction of isolated caudate portal vein in left liver graft. Liver Transpl. 10: 1163-1165. *

• Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC 2007 Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am. J. Gastroenterol. 102: 412-429. *

• Kosuge M, Takizawa H, Maehashi H, Matsuura T, Matsufuji S 2007 A comprehensive gene expression analysis of human hepatocellular carcinoma cell lines as components of a bioartificial liver using a radial flow bioreactor. Liver Int. 27: 101-108. *

• Krahenbuhl S, Brass EP, Hoppel CL 2000 Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis. Hepatology 31: 1217-1223. *

• Krisper P, Haditsch B, Stauber R, Jung A, Stadlbauer V, Trauner M, Holzer H, Schneditz D 2005 In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J. Hepatol. 43: 451-457. *

• Kullak-Ublick GA, Beuers U, Fahney C, Hagenbuch B, Meier PJ, Paumgartner G 1997 Identification and functional characterization of the promoter region of the human organic anion transporting polypeptide gene. Hepatology 26: 991-997. *

• Kullak-Ublick GA, Beuers U, Meier PJ, Domdey H, Paumgartner G 1996 Assignment of the human organic anion transporting polypeptide (OATP) gene to chromosome 12p12 by fluorescence in situ hybridization. J. Hepatol. 25: 985-987. *

• Kyoden Y, Sugawara Y, Matsui Y, Kishi Y, Akamatsu N, Makuuchi M 2005 Hepatofugal portal flow due to acute cellular rejection. Abdom. Imaging 30: 303-305. *

• Li LJ, Du WB, Zhang YM, Li J, Pan XP, Chen JJ, Cao HC, Chen Y, Chen YM 2006 Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs. J. Hepatol. 44: 317-324. *

• Liu Q, Duan ZP, Ha da K, Bengmark S, Kurtovic J, Riordan SM 2004 Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39: 1441-1449. *

• Ma X, Cheung C, Krausz KW, Shah Y, Wang T, Idle JR, Gonzalez FJ 2008 A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab. Dispos. Sep 17 [Epub ahead of print]. *

• Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ 2007 The pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab. Dispos. 35: 194-200. *

• Makuuchi M, Miller CM, Olthoff K, Schwartz M 2004 Adult-adult living donor liver transplantation. J. Gastrointest. Surg. 8: 303-312.

• Makuuchi M, Sano K 2004 The surgical approach to HCC: our progress and results in Japan. Liver Transpl. 10 Suppl. 2: S46-S52. *

• Matsushita T, Yagi T, Hardin JA, Cragun JD, Crow FW, Bergen HR 3rd, Gores GJ, Nyberg SL 2003 Apoptotic cell death and function of cryopreserved porcine hepatocytes in a bioartificial liver. Cell Transplant. 12: 109-121.

• McClave SA, Chang WK, Dhaliwal R, Heyland DK 2006 Nutrition support in acute pancreatitis: a systematic review of the literature. JPEN J. Parenter. Enteral Nutr. 30: 143-156. *

• Meaney S, Bjorkhem I 2004 On the role of oxysterols in regulation of cholesterol homeostasis by nuclear receptors. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 26. June 18-19. *

• Metz T, Haque T, Chen H, Prakash S, Amre D, Das SK 2006 Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-alpha. Drug Deliv. 13: 331-337.

• Metz T, Jones ML, Chen H, Halim T, Mirzaei M, Haque T, Amre D, Das SK, Prakash S 2005 A new method for targeted drug delivery using polymeric microcapsules: implications for treatment of Crohn's disease. Cell Biochem. Biophys. 43: 77-86.

• Min AD, Theise ND 2004 Prospects for cell-based therapies for liver disease. Panminerva Med. 46: 43-48. *

• Mizumoto H, Funatsu K 2004 Liver regeneration using a hybrid artificial liver support system. Artif. Organs 28: 53-57. *

• Mullhaupt B, Kullak-Ublick GA, Ambuhl P, Maggiorini M, Stocker R, Kadry Z, Clavien PA, Renner EL 2002 First clinical experience with Molecular Adsorbent Recirculating System (MARS) in six patients with severe acute on chronic liver failure. Liver 22 Suppl. 2: 59-62.

• Mullon C, Pitkin Z 1999 The HepatAssist(R) Bioartificial Liver Support System: clinical study and pig hepatocyte process. Expert Opin. Investig. Drugs 8: 229-235.

• Nagata K, Suzuki H, Sakaguchi S 2007 Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J. Toxicol. Sci. 32: 453-468. *

• Naruse K 2005 Artificial liver support: future aspects. J. Artif. Organs 8: 71-76. *

• Naruse K, Nagashima H, Sakai Y, Kokudo N, Makuuchi M 2005 Development and perspectives of perfusion treatment for liver failure. Surg. Today 35: 507-517.

• Nguyen TH, Mai G, Villiger P, Oberholzer J, Salmon P, Morel P, Buhler L, Trono D 2005 Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. J. Hepatol. 43: 1031-1037. *

• Nyberg SL, Hardin J, Amiot B, Argikar UA, Remmel RP, Rinaldo P 2005 Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver. Liver Transpl. 11: 901-910. *

• Nyberg SL, Mann HJ, Remmel RP, Hu WS, Cerra FB 1993 Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver. ASAIO J. 39: M252-M256.

• O’Farrelly C 2003 Hepatic stem cells - potential for the future. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 49. September 12 - 13. *

• Ohashi K, Yokoyama T, Yamato M, Kuge H, Kanehiro H, Tsutsumi M, Amanuma T, Iwata H, Yang J, Okano T, Nakajima Y 2007 Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets. Nat. Med. 13: 880-885. *

• Okubo H, Takei Y, Serizawa N, Enomoto N, Ikejima K, Sato N 2007 Orthotopic hepatocellular carcinoma model with a controlled and reproducible tumorigenicity. J. Gastroenterol. Hepatol. 22: 423-428. *

• Patel T, Singh P 2007 Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr. Opin. Gastroenterol. 23: 317-323.

• Patzer II JF, Lopez RC, Zhu Y, Wang ZF, Mazariegos GV, Fung JJ 2002 Bioartificial liver assist devices in support of patients with liver failure. Hepatobiliary Pancreat. Dis. Int. 1: 18-25. *

• Pazzi P, Morsiani E, Vilei MT, Granato A, Rozga J, Demetriou AA, Muraca M 2002 Serum bile acids in patients with liver failure supported with a bioartificial liver. Aliment. Pharmacol. Ther. 16: 1547-1554. *

• Poyck PP, Hoekstra R, Vermeulen JL, van Wijk AC, Chamuleau RA, Hakvoort TB, van Gulik TM, Lamers WH 2008 Expression of glutamine synthetase and carbamoylphosphate synthetase I in a bioartificial liver: markers for the development of zonation in vitro. Cells Tissues Organs Mar 20 [Epub ahead of print].

• Poyck PP, van Wijk AC, van der Hoeven TV, de Waart DR, Chamuleau RA, van Gulik TM, Oude Elferink RP, Hoekstra R 2008 Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J. Hepatol. 48: 266-275. *

• Prakash S, Bhathena J 2005 Live bacterial cells as orally delivered therapeutics. Expert Opin. Biol. Ther. 5: 1281-1301.

• Prakash S, Martoni C 2006 Toward a new generation of therapeutics: artificial cell targeted delivery of live cells for therapy. Appl. Biochem. Biotechnol. 128: 1-22.

• Rifai K, Manns MP 2006 Review article: clinical experience with Prometheus. Ther. Apher. Dial. 10: 132-137.

• Rodriguez-Luna H, Vargas HE, Byrne T, Rakela J 2005 Artificial neural network and tissue genotyping of hepatocellular carcinoma in liver-transplant recipients: prediction of recurrence. Transplantation 79: 1737-1740.

• Rosenthal P 2000 Digestive disease week 2000. American association for the study of liver diseases. IDrugs 3: 868-871.

• Roy P, Washizu J, Tilles AW, Yarmush ML, Toner M 2001 Effect of flow on the detoxification function of rat hepatocytes in a bioartificial liver reactor. Cell Transplant. 10: 609-614.

• Russo MW, Brown RS Jr 2003 Ethical issues in living donor liver transplantation. Curr. Gastroenterol. Rep. 5: 26-30.

• Santoro A, Mancini E, Ferramosca E, Faenza S 2007 Liver support systems. Contrib. Nephrol. 156: 396-404.

• Selden C, Hodgson H 2004 Cellular therapies for liver replacement. Transpl. Immunol. 12: 273-288.

• Sherlock S 1999 Biotechnologies and liver diseases. Forum (Genova) 9 (3 Suppl. 3): 63-66.

• Shingel KI, Faure MP, Azoulay L, Roberge C, Deckelbaum RJ 2008 Solid emulsion gel as a vehicle for delivery of polyunsaturated fatty acids: implications for tissue repair, dermal angiogenesis and wound healing. J. Tissue Eng. Regen. Med. Jul 21 [Epub ahead of print].

• Shito M, Tilles AW, Tompkins RG, Yarmush ML, Toner M 2003 Efficacy of an extracorporeal flat-plate bioartificial liver in treating fulminant hepatic failure. J. Surg. Res. 111: 53-62. *

• Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH 2002 The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif. Organs 26: 103-110. *

• Strain AJ, Neuberger JM 2002 A bioartificial liver - state of the art. Science 295: 1005-1009. *

• Strassburg CP 2005 Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70. *

• Streetz KL 2008 Bio-artificial liver devices - tentative, but promising progress. J. Hepatol. 48: 189-191. *

• Sugawara Y, Makuuchi M, Takayama T, Imamura H 2001 Living-related liver transplantation for primary biliary cirrhosis. Transplantation 72: 1087-1091.

• Sugawara Y, Makuuchi M, Takayama T, Imamura H, Kaneko J, Ohkubo T 2002 Safe donor hepatectomy for living related liver transplantation. Liver Transpl. 8: 58-62. *

• Summerfield JA 2001 Liver failure. ENCYCLOPEDIA OF LIFE SCIENCES Nature Publishing Group www.els.net. *

• Susick R, Moss N, Kubota H, Lecluyse E, Hamilton G, Luntz T, Ludlow J, Fair J, Gerber D, Bergstrand K, White J, Bruce A, Drury O, Gupta S, Reid LM 2001 Hepatic progenitors and strategies for liver cell therapies. Ann. N. Y. Acad. Sci. 944: 398-419.

• Takahashi M, Ishikura H, Takahashi C, Nakajima Y, Matsushita M, Matsue H, Sato K, Sato K, Noto H, Taguchi K, et al 1993 Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum. ASAIO J. 39: M242-M246.

• Takahashi M, Sakurai M, Enosawa S, Omasa T, Tsuruoka S, Matsumura T 2006 Double-compartment cell culture apparatus: construction and biochemical evaluation for bioartificial liver support. Cell. Transplant. 15: 945-952.

• Tamura S, Sugawara Y, Kaneko J, Matsui Y, Togashi J, Makuuchi M 2007 Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int. 27: 86-94. *

• Tamura S, Sugawara Y, Kaneko J, Togashi J, Matsui Y, Yamashiki N, Kokudo N, Makuuchi M 2008 Recurrence of cholestatic liver disease after living donor liver transplantation. World J. Gastroenterol. 14: 5105-5109. *

• Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Murai N, Makuuchi M 2004 Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: a single-center experience at the University of Tokyo. Transplant. Proc. 36: 3242-3244. *

• te Velde AA, Ladiges NC, Flendrig LM, Chamuleau RA 1995 Functional activity of isolated pig hepatocytes attached to different extracellular matrix substrates. Implication for application of pig hepatocytes in a bioartificial liver. J. Hepatol. 23: 184-192. *

• Tilles AW, Berthiaume F, Yarmush ML, Tompkins RG, Toner M 2002 Bioengineering of liver assist devices. J. Hepatobiliary Pancreat. Surg. 9: 686-696.

• Tilles AW, Berthiaume F, Yarmush ML, Toner M 2002 Critical issues in bioartificial liver development. Technol. Health Care 10: 177-186.

• Ting PP, Demetriou AA 2000 Clinical experience with artificial liver support systems. Can. J. Gastroenterol. 14 Suppl. D: 79D-84D.

• Trittenwein G, Boigner H, Mostafa G, Burda G, Muhl A, Amann G, Pollak A 2006 Bridging to transplantation in acute liver failure in a 7-month-old infant. Wien. Klin. Wochenschr. 118: 298-301.

• van de Kerkhove MP, Poyck PP, Deurholt T, Hoekstra R, Chamuleau RA, van Gulik TM 2005 Liver support therapy: an overview of the AMC-bioartificial liver research. Dig. Surg. 22: 254-264.

• von Weizsacker F 2003 Liver cell based strategies. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 105. October 17 - 19. *

• Williams R 2008 The pervading influence of alcoholic liver disease in hepatology. Alcohol Alcohol. 43: 393-397.

• Wu J, Zheng SS 2004 Liver transplantation in China: problems and their solutions. Hepatobiliary Pancreat. Dis. Int. 3: 170-174. *

• Zhang F, He Y, Duan Z 2008 Changes of high mobility group box 1 in serum of pig acute hepatic failure model and significance. J. Huazhong Univ. Sci. Technolog. Med. Sci. 28: 52-55.

• Zhou X, Jamil A, Nash A, Chan J, Trim N, Iredale JP, Benyon RC 2006 Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: implications for regulation of liver fibrosis. J. Biol. Chem. 281: 39757-39765. *

Number of references = 151

www psc-literature.org